THERAPEUTIC COMPOSITIONS COMPRISING beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine ACID AND DERIVATIVE isoindole carboxylic acid and its uses. COMPOUND.

Composition which may include an inhibitor of viral hepatitis C polymerase, or pharmaceutically acceptable salts or prodrugs and viral protease inhibitor of hepatitis C, or their pharmaceutically acceptable salts or prodrugs. Methods for treating a disease condition such as a pharmaceutically acceptable infection with hepatitis C, hepatic fibrosis and / or abnormal liver function with an inhibitor of the viral polymerase of hepatitis C, or salts or prodrugs and inhibitor viral hepatitis C protease or pharmaceutically acceptable salts or prodrugs. Claim 1: A composition comprising a first compound, or a pharmaceutically acceptable salt or prodrug thereof wherein the first compound is of formula (1); and a second compound, or a pharmaceutically acceptable salt or prodrug thereof, wherein the second compound is of formula (2). Claim 11: The composition according to any of claims 1 to 2, wherein the composition further comprises one or more additional therapeutic agents. Claim 12: The composition according to claim 11, wherein the additional therapeutic agent is selected from the group consisting of a nucleoside analogue, pirfenidone a pirfenidone analog, an inhibitor of RNA dependent polymerase RNA NS5B, antagonist tumor necrosis factor, thymosin-a, interferon-g (IFN-g), interferon-a (IFN-a), 3'-azidothymidine, 2 ', 3'-dideoxyinosine, 2', 3'-dideoxycytidine, 2- 3-didehydro-2 ', 3'-dideoxythymidine, combivir, abacavir, adefovir dipoxil, cidofovir, ritonavir, an inhibitor of inosine monophosphate dehydrogenase, an interferon, a protease inhibitor additional NS3, NS5b polymerase inhibitor, and an inhibitor NS3 helicase. Claim 25: Use of a first compound or a pharmaceutically acceptable salt or prodrug thereof, wherein used for the preparation of a medicament for ameliorating or treating a disease condition in a patient population; where the first compound is of formula (1), where the first compound is manufactured for use in combination with a second compound or a pharmaceutically acceptable salt or prodrug thereof; wherein the second compound is of formula (2), and where the disease condition is selected from the group consisting of infection with hepatitis C, hepatic fibrosis, and impaired liver function.